Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:CHMA NASDAQ:CMRX NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.99+13.9%$4.37$2.12▼$6.43$597.32M1.824.03 million shs12.10 million shsCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AXERSXeris Biopharma$8.18+4.2%$7.02$2.69▼$8.35$1.32B0.121.91 million shs1.58 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%+5.64%+58.89%+80.97%+26.91%CHMAChiasma0.00%0.00%0.00%0.00%0.00%CMRXChimerix0.00%0.00%0.00%0.00%+856.97%XERSXeris Biopharma0.00%+5.96%+4.47%+75.16%+185.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.99+13.9%$4.37$2.12▼$6.43$597.32M1.824.03 million shs12.10 million shsCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AXERSXeris Biopharma$8.18+4.2%$7.02$2.69▼$8.35$1.32B0.121.91 million shs1.58 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%+5.64%+58.89%+80.97%+26.91%CHMAChiasma0.00%0.00%0.00%0.00%0.00%CMRXChimerix0.00%0.00%0.00%0.00%+856.97%XERSXeris Biopharma0.00%+5.96%+4.47%+75.16%+185.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$10.2971.71% UpsideCHMAChiasma 0.00N/AN/AN/ACMRXChimerix 2.00Hold$8.53-0.08% DownsideXERSXeris Biopharma 2.83Moderate Buy$7.08-13.41% DownsideCurrent Analyst Ratings BreakdownLatest AQST, XERS, CHMA, and CMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025AQSTAquestive TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.009/3/2025AQSTAquestive TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/19/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.008/13/2025AQSTAquestive TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/12/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M10.38N/AN/A($0.66) per share-9.08CHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94XERSXeris Biopharma$203.07M6.50N/AN/A($0.20) per share-40.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$44.14M-$0.70N/AN/AN/A-147.38%N/A-63.87%11/3/2025 (Estimated)CHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/ACMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%N/AXERSXeris Biopharma-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)Latest AQST, XERS, CHMA, and CMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AQSTAquestive Therapeutics-$0.18-$0.14+$0.04-$0.14$11.32 million$10.00 million8/7/2025Q2 2025XERSXeris Biopharma-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A3.533.18CHMAChiasmaN/A7.917.08CMRXChimerixN/A6.336.33XERSXeris BiopharmaN/A1.951.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%CHMAChiasma61.68%CMRXChimerix45.42%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics7.85%CHMAChiasma8.30%CMRXChimerix13.10%XERSXeris Biopharma4.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.72 million91.90 millionOptionableCHMAChiasma8557.89 millionN/ANot OptionableCMRXChimerix9093.80 million78.15 millionOptionableXERSXeris Biopharma290161.48 million154.12 millionOptionableAQST, XERS, CHMA, and CMRX HeadlinesRecent News About These CompaniesStrs Ohio Buys New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 24, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Price Down 7.2% - Should You Sell?September 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Should You Buy?September 19, 2025 | marketbeat.comAQR Capital Management LLC Has $5.20 Million Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 15, 2025 | marketbeat.comInsider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,500 Shares of StockSeptember 14, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires Shares of 255,560 Xeris Biopharma Holdings, Inc. $XERSSeptember 14, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Director Sells $119,660.00 in StockSeptember 13, 2025 | insidertrades.comFred Alger Management LLC Buys New Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 13, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 12, 2025 | marketbeat.comWhat Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest Down 26.7% in AugustSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $9.78 Million Stock Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 8, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to BuySeptember 8, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 7, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stock Holdings Raised by Graham Capital Management L.P.September 7, 2025 | marketbeat.comBosun Asset Management LLC Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 6, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High - Time to Buy?September 5, 2025 | marketbeat.comXeris In Recorlev-Fuelled Growth: Why I Choose To BuySeptember 5, 2025 | seekingalpha.comPDT Partners LLC Buys New Shares in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comIeq Capital LLC Boosts Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comQuarry LP Makes New $388,000 Investment in Xeris Biopharma Holdings, Inc. $XERSSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025Biotech Sector May Flip to Market Leader by Year-EndBy Ryan Hasson | September 15, 2025Replace Your Fixed Income With This Dividend ETFBy Jordan Chussler | September 24, 2025Vertical Aerospace Presents Its Blueprint for Sector LeadershipBy Jeffrey Neal Johnson | September 23, 2025AQST, XERS, CHMA, and CMRX Company DescriptionsAquestive Therapeutics NASDAQ:AQST$5.99 +0.73 (+13.88%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$6.10 +0.11 (+1.84%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Chiasma NASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Chimerix NASDAQ:CMRXChimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Xeris Biopharma NASDAQ:XERS$8.18 +0.33 (+4.20%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$8.22 +0.04 (+0.55%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
